StockNews.com initiated coverage on shares of Trinity Biotech (NASDAQ:TRIB – Free Report) in a report issued on Thursday morning. The brokerage issued a hold rating on the stock.
Trinity Biotech Stock Performance
NASDAQ:TRIB opened at $0.80 on Thursday. The firm’s 50-day moving average is $0.90 and its 200-day moving average is $1.54. Trinity Biotech has a 52-week low of $0.74 and a 52-week high of $3.55. The company has a market cap of $14.44 million, a price-to-earnings ratio of -0.35 and a beta of 1.03.
Institutional Trading of Trinity Biotech
An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC lifted its position in Trinity Biotech plc (NASDAQ:TRIB – Free Report) by 7.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 359,810 shares of the company’s stock after purchasing an additional 26,100 shares during the quarter. Hunter Associates Investment Management LLC owned 4.72% of Trinity Biotech worth $390,000 at the end of the most recent reporting period. 78.97% of the stock is currently owned by hedge funds and other institutional investors.
About Trinity Biotech
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Recommended Stories
- Five stocks we like better than Trinity Biotech
- P/E Ratio Calculation: How to Assess Stocks
- Price Plunge in Roblox Presents Opportunity for Robust Gains
- The Risks of Owning Bonds
- Billions in Buybacks: 4 Stocks Rewarding Shareholders Now
- Ride Out The Recession With These Dividend Kings
- 3 Steel Stocks to Gain Strength as Tariffs Reshape the Market
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
